Leodizcol (Baclofen)

Baclofen is a GABA_B receptor agonist. It binds to these receptors in the spinal cord, inhibiting the release of excitatory neurotransmitters. This reduces neuronal firing that contributes to muscle over‑activity, thereby decreasing spasticity and improving muscle control.

The dosage of Leodizcol is individualized. A qualified prescriber determines the appropriate dose based on the patient’s condition, response, and tolerability. Dosage adjustments may be needed over time, especially when initiating therapy or modifying other medications.

Safety data for baclofen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Leodizcol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leodizcol (baclofen) is a GABA_B agonist, whereas alternatives such as tizanidine act on α‑2 adrenergic receptors and dantrolene works directly on skeletal muscle. Baclofen’s central mechanism often provides effective spasticity control with a distinct side‑effect profile, making it a first‑line choice for many neurologic conditions.

Leodizcol should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Leodizcol is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The medication is swallowed whole and should be taken at the same times each day to maintain consistent blood levels.

Serious risks include seizures, hallucinations, severe hypotension, respiratory depression, and allergic reactions such as rash or angioedema. Patients should be monitored closely for these events, especially when starting therapy, adjusting doses, or combining with other central nervous system depressants.

Leodizcol is contraindicated in patients with known hypersensitivity to baclofen or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking multiple CNS depressants without close medical supervision.